Journal: Biomedical Journal

Article Title: Inhibition of infantile hemangioma growth and promotion of apoptosis via VEGF/PI3K/Akt axis by 755-nm long-pulse alexandrite laser

doi: 10.1016/j.bj.2023.100675

Figure Lengend Snippet: The sequences of primers.

Article Snippet: The membranes were gently agitated and incubated with antibodies against the following proteins: VEGFA (BA0407, Boster, Wuhan, China, 1 : 1000), VEGFR2 (A00901-2, Boster, Wuhan, China, 1 : 1000), p-Akt (#4691, Cell Signaling Technology, MA, United States, 1 : 1000), p-Akt (#4060, Cell Signaling Technology, MA, United States, 1 : 2000), VEGF 165a (ab69479, Abcam, Cambridge, MA, United States), VEGF 165b (GTX52502, GeneTex, Irvine, CA, United States), glycolytic enzyme glyceraldehyde 3-phosphate dehydrogenase (GAPDH) (A00227-4, Boster, Wuhan, China, 1 : 1000), at 4 °C overnight.

Techniques:

Journal: Biomedical Journal

Article Title: Inhibition of infantile hemangioma growth and promotion of apoptosis via VEGF/PI3K/Akt axis by 755-nm long-pulse alexandrite laser

doi: 10.1016/j.bj.2023.100675

Figure Lengend Snippet: The downregulation of VEGFA expression and suppression of the PI3K/AKT signaling pathway in HemECs by long-pulsed Alexandrite laser (755 nm). (A) Expression analysis of VEGFA, VEGFR2, PI3K, and Akt using quantitative RT-PCR. (B) Western blot analysis of the relative protein expression levels of VEGFA, VEGFR2, p-Akt, and Akt in HemECs. ∗∗ p <0.01, ∗∗∗ p <0.001 vs. control. Abbreviations: HemECs: human hemangioma endothelial cells; VEGF: vascular endothelial growth factor; VEGFR: vascular endothelial growth factor receptor; PI3K: phosphoinositide 3-kinase; Akt: protein kinase B.

Article Snippet: The membranes were gently agitated and incubated with antibodies against the following proteins: VEGFA (BA0407, Boster, Wuhan, China, 1 : 1000), VEGFR2 (A00901-2, Boster, Wuhan, China, 1 : 1000), p-Akt (#4691, Cell Signaling Technology, MA, United States, 1 : 1000), p-Akt (#4060, Cell Signaling Technology, MA, United States, 1 : 2000), VEGF 165a (ab69479, Abcam, Cambridge, MA, United States), VEGF 165b (GTX52502, GeneTex, Irvine, CA, United States), glycolytic enzyme glyceraldehyde 3-phosphate dehydrogenase (GAPDH) (A00227-4, Boster, Wuhan, China, 1 : 1000), at 4 °C overnight.

Techniques: Expressing, Quantitative RT-PCR, Western Blot, Control

Journal: Biomedical Journal

Article Title: Inhibition of infantile hemangioma growth and promotion of apoptosis via VEGF/PI3K/Akt axis by 755-nm long-pulse alexandrite laser

doi: 10.1016/j.bj.2023.100675

Figure Lengend Snippet: The downregulation of VEGFA expression and suppression of PI3K/AKT signaling pathway activation in xenograft by long-pulsed Alexandrite laser (755 nm). (A) Analysis of the expression levels of VEGFA, VEGFR2, PI3K, and Akt using quantitative RT-PCR. (B) Western blot analysis of the protein expression levels of VEGFA, VEGFR2, p-Akt, and Akt in xenograft. (C) Detection of the relative protein expression levels of VEGFA 165a and VEGFA 165b in xenograft using western blot. ∗ p <0.05, ∗∗ p <0.01, ∗∗∗ p <0.001 vs. control. Abbreviations: VEGF: vascular endothelial growth factor; VEGFR: vascular endothelial growth factor receptor; PI3K: phosphoinositide 3-kinase; Akt: protein kinase B.

Article Snippet: The membranes were gently agitated and incubated with antibodies against the following proteins: VEGFA (BA0407, Boster, Wuhan, China, 1 : 1000), VEGFR2 (A00901-2, Boster, Wuhan, China, 1 : 1000), p-Akt (#4691, Cell Signaling Technology, MA, United States, 1 : 1000), p-Akt (#4060, Cell Signaling Technology, MA, United States, 1 : 2000), VEGF 165a (ab69479, Abcam, Cambridge, MA, United States), VEGF 165b (GTX52502, GeneTex, Irvine, CA, United States), glycolytic enzyme glyceraldehyde 3-phosphate dehydrogenase (GAPDH) (A00227-4, Boster, Wuhan, China, 1 : 1000), at 4 °C overnight.

Techniques: Expressing, Activation Assay, Quantitative RT-PCR, Western Blot, Control

Journal: Biomedical Journal

Article Title: Inhibition of infantile hemangioma growth and promotion of apoptosis via VEGF/PI3K/Akt axis by 755-nm long-pulse alexandrite laser

doi: 10.1016/j.bj.2023.100675

Figure Lengend Snippet: Representative immunohistochemical staining of VEGFA, VEGFR2, PI3K, and Akt in tumor sections from each group of mice (magnification, × 400; scale bar, 25 μm). Abbreviations: VEGF: vascular endothelial growth factor; VEGFR: vascular endothelial growth factor receptor; PI3K: phosphoinositide 3-kinase; Akt: protein kinase B.

Article Snippet: The membranes were gently agitated and incubated with antibodies against the following proteins: VEGFA (BA0407, Boster, Wuhan, China, 1 : 1000), VEGFR2 (A00901-2, Boster, Wuhan, China, 1 : 1000), p-Akt (#4691, Cell Signaling Technology, MA, United States, 1 : 1000), p-Akt (#4060, Cell Signaling Technology, MA, United States, 1 : 2000), VEGF 165a (ab69479, Abcam, Cambridge, MA, United States), VEGF 165b (GTX52502, GeneTex, Irvine, CA, United States), glycolytic enzyme glyceraldehyde 3-phosphate dehydrogenase (GAPDH) (A00227-4, Boster, Wuhan, China, 1 : 1000), at 4 °C overnight.

Techniques: Immunohistochemical staining, Staining

Journal: Journal of Neuroinflammation

Article Title: Succinate-induced macrophage polarization and RBP4 secretion promote vascular sprouting in ocular neovascularization

doi: 10.1186/s12974-023-02998-1

Figure Lengend Snippet: Effect of RBP4 on sprouting in vivo and in vitro. HUVECs were treated with 10 ng/ml RBP4 for 48 h, with or without 1 μM Ki8751 pretreatment for 12 h. A Relative mRNA expression of ANGPT2, TIE1, HEY1 and DLL4 in RBP4-treated HUVECs ( n = 3). B Relative mRNA expression of ANGPT2, TIE1, HEY1 and DLL4 in the control, RBP4 and RBP4 + Ki8751 groups ( n = 3). C , D Protein levels of VEGFR2 in the three groups ( n = 3). E Immunofluorescence staining of DAPI (blue) and VEGFR2 (red) in HUVECs. Scale bar: 50 μm. F Co-IP examination of VEGFR2-RBP4 interaction. H , J , K Retinal IB4 staining of P14 in OIR and relative number of tip cells as well as filopodia. Scale bar: 200 μm ( n = 3). G , I Choroidal sprouting analysis in three groups ( n = 3). Scale bar: 500 μm. * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001

Article Snippet: Administration of the VEGFR2 inhibitor Ki8751 (1 μM for 12 h, #HY-12038, MCE) reduced VEGFR2 expression and attenuated RBP4 promotion of ANGPT2 and TIE1 as well as inhibition of HEY1 and DLL4 (Fig. B).

Techniques: In Vivo, In Vitro, Expressing, Control, Immunofluorescence, Staining, Co-Immunoprecipitation Assay